Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma.MedImmune has an exclusive relationship with Immunocore for the development of IMCgp100 in combination with MEDI4736 and/or tremelimumab, and will have first right of negotiation for the future commercial development of these combinations for tumours expressing gp100.
Detail:
www.prnewswire.com/news-releases/immunocore-and-medimmune-announce-new-collaboration-to-conduct-immuno-oncology-combination-trails-in-melanoma-500030991.html
Detail:
www.prnewswire.com/news-releases/immunocore-and-medimmune-announce-new-collaboration-to-conduct-immuno-oncology-combination-trails-in-melanoma-500030991.html
No comments:
Post a Comment